Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 10MG
USFDA APPLICATION NUMBER - 202293
DOSAGE - TABLET;ORAL - 5MG
USFDA APPLICATION NUMBER - 202293
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Neelkanth MineChem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Disintegrants & Superdisintegrants
Lubricants & Glidants
Thickeners and Stabilizers
Granulation
Co-Processed Excipients
Controlled & Modified Release
Film Formers & Plasticizers
Taste Masking
Topical
Rheology Modifiers
Emulsifying Agents
Chewable & Orodispersible Aids
Parenteral
API Stability Enhancers
Surfactant & Foaming Agents
Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
64
PharmaCompass offers a list of Dapagliflozin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dapagliflozin manufacturer or Dapagliflozin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dapagliflozin manufacturer or Dapagliflozin supplier.
PharmaCompass also assists you with knowing the Dapagliflozin API Price utilized in the formulation of products. Dapagliflozin API Price is not always fixed or binding as the Dapagliflozin Price is obtained through a variety of data sources. The Dapagliflozin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dapagliflozin Amorphous manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dapagliflozin Amorphous, including repackagers and relabelers. The FDA regulates Dapagliflozin Amorphous manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dapagliflozin Amorphous API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dapagliflozin Amorphous manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dapagliflozin Amorphous supplier is an individual or a company that provides Dapagliflozin Amorphous active pharmaceutical ingredient (API) or Dapagliflozin Amorphous finished formulations upon request. The Dapagliflozin Amorphous suppliers may include Dapagliflozin Amorphous API manufacturers, exporters, distributors and traders.
click here to find a list of Dapagliflozin Amorphous suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dapagliflozin Amorphous DMF (Drug Master File) is a document detailing the whole manufacturing process of Dapagliflozin Amorphous active pharmaceutical ingredient (API) in detail. Different forms of Dapagliflozin Amorphous DMFs exist exist since differing nations have different regulations, such as Dapagliflozin Amorphous USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dapagliflozin Amorphous DMF submitted to regulatory agencies in the US is known as a USDMF. Dapagliflozin Amorphous USDMF includes data on Dapagliflozin Amorphous's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dapagliflozin Amorphous USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dapagliflozin Amorphous suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dapagliflozin Amorphous Drug Master File in Japan (Dapagliflozin Amorphous JDMF) empowers Dapagliflozin Amorphous API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dapagliflozin Amorphous JDMF during the approval evaluation for pharmaceutical products. At the time of Dapagliflozin Amorphous JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dapagliflozin Amorphous suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dapagliflozin Amorphous Drug Master File in Korea (Dapagliflozin Amorphous KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dapagliflozin Amorphous. The MFDS reviews the Dapagliflozin Amorphous KDMF as part of the drug registration process and uses the information provided in the Dapagliflozin Amorphous KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dapagliflozin Amorphous KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dapagliflozin Amorphous API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dapagliflozin Amorphous suppliers with KDMF on PharmaCompass.
A Dapagliflozin Amorphous CEP of the European Pharmacopoeia monograph is often referred to as a Dapagliflozin Amorphous Certificate of Suitability (COS). The purpose of a Dapagliflozin Amorphous CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dapagliflozin Amorphous EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dapagliflozin Amorphous to their clients by showing that a Dapagliflozin Amorphous CEP has been issued for it. The manufacturer submits a Dapagliflozin Amorphous CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dapagliflozin Amorphous CEP holder for the record. Additionally, the data presented in the Dapagliflozin Amorphous CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dapagliflozin Amorphous DMF.
A Dapagliflozin Amorphous CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dapagliflozin Amorphous CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dapagliflozin Amorphous suppliers with CEP (COS) on PharmaCompass.
A Dapagliflozin Amorphous written confirmation (Dapagliflozin Amorphous WC) is an official document issued by a regulatory agency to a Dapagliflozin Amorphous manufacturer, verifying that the manufacturing facility of a Dapagliflozin Amorphous active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dapagliflozin Amorphous APIs or Dapagliflozin Amorphous finished pharmaceutical products to another nation, regulatory agencies frequently require a Dapagliflozin Amorphous WC (written confirmation) as part of the regulatory process.
click here to find a list of Dapagliflozin Amorphous suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dapagliflozin Amorphous as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dapagliflozin Amorphous API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dapagliflozin Amorphous as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dapagliflozin Amorphous and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dapagliflozin Amorphous NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dapagliflozin Amorphous suppliers with NDC on PharmaCompass.
Dapagliflozin Amorphous Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dapagliflozin Amorphous GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dapagliflozin Amorphous GMP manufacturer or Dapagliflozin Amorphous GMP API supplier for your needs.
A Dapagliflozin Amorphous CoA (Certificate of Analysis) is a formal document that attests to Dapagliflozin Amorphous's compliance with Dapagliflozin Amorphous specifications and serves as a tool for batch-level quality control.
Dapagliflozin Amorphous CoA mostly includes findings from lab analyses of a specific batch. For each Dapagliflozin Amorphous CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dapagliflozin Amorphous may be tested according to a variety of international standards, such as European Pharmacopoeia (Dapagliflozin Amorphous EP), Dapagliflozin Amorphous JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dapagliflozin Amorphous USP).
